JP2024536798A5 - - Google Patents

Info

Publication number
JP2024536798A5
JP2024536798A5 JP2024517477A JP2024517477A JP2024536798A5 JP 2024536798 A5 JP2024536798 A5 JP 2024536798A5 JP 2024517477 A JP2024517477 A JP 2024517477A JP 2024517477 A JP2024517477 A JP 2024517477A JP 2024536798 A5 JP2024536798 A5 JP 2024536798A5
Authority
JP
Japan
Prior art keywords
seq
antibody
cancer
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024517477A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024536798A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/120481 external-priority patent/WO2023046003A1/zh
Publication of JP2024536798A publication Critical patent/JP2024536798A/ja
Publication of JP2024536798A5 publication Critical patent/JP2024536798A5/ja
Pending legal-status Critical Current

Links

JP2024517477A 2021-09-23 2022-09-22 抗体薬物コンジュゲート並びにその製造方法及び医薬用途 Pending JP2024536798A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111116842.X 2021-09-23
CN202111116842 2021-09-23
PCT/CN2022/120481 WO2023046003A1 (zh) 2021-09-23 2022-09-22 抗体药物偶联物及其制备方法和医药用途

Publications (2)

Publication Number Publication Date
JP2024536798A JP2024536798A (ja) 2024-10-08
JP2024536798A5 true JP2024536798A5 (enExample) 2025-10-09

Family

ID=85720088

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024517477A Pending JP2024536798A (ja) 2021-09-23 2022-09-22 抗体薬物コンジュゲート並びにその製造方法及び医薬用途

Country Status (9)

Country Link
US (1) US20240390509A1 (enExample)
EP (1) EP4406974A4 (enExample)
JP (1) JP2024536798A (enExample)
KR (1) KR20240058146A (enExample)
CN (1) CN118139891A (enExample)
AU (1) AU2022350725A1 (enExample)
CA (1) CA3232425A1 (enExample)
TW (1) TW202327663A (enExample)
WO (1) WO2023046003A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7767613B2 (ja) 2021-11-15 2025-11-11 システィミューン,インコーポレイテッド 二重特異性抗体-カンプトテシン薬物複合体及びその製薬的使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2235269C (en) 1995-10-19 2006-09-19 Bristol-Myers Squibb Company Monoclonal antibody br110 and uses thereof
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
US7420040B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
SG11201401699WA (en) * 2011-11-11 2014-09-26 Rinat Neuroscience Corp Antibodies specific for trop-2 and their uses
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
CN102827282B (zh) 2012-09-04 2015-02-11 林红 人源抗Trop-2基因工程抗体IgG及其应用
SG10201902571VA (en) * 2013-12-25 2019-04-29 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
CN107446050A (zh) * 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 Trop2阳性疾病治疗的化合物及方法
CN110903395A (zh) * 2018-09-14 2020-03-24 四川科伦博泰生物医药股份有限公司 抗体、偶联物及其制备方法和用途
US12534532B2 (en) * 2018-10-26 2026-01-27 Crage Medical Co., Limited CLL1-targeting antibody and application thereof
WO2020228604A1 (zh) 2019-05-10 2020-11-19 江苏豪森药业集团有限公司 抗trop-2抗体、其抗原结合片段及其医药用途
CN112168978B (zh) * 2019-07-03 2022-01-11 北京大学 一种抗体偶联药物及其药物组合物与应用
WO2021190480A1 (zh) * 2020-03-24 2021-09-30 上海翰森生物医药科技有限公司 抗体-药物偶联物及其医药用途
TWI889920B (zh) * 2020-10-14 2025-07-11 大陸商上海翰森生物醫藥科技有限公司 抗trop-2抗體、其抗原結合片段或其突變體、及其醫藥用途

Similar Documents

Publication Publication Date Title
TWI891749B (zh) 抗體-藥物偶聯物及其醫藥用途
ES2985352T3 (es) Anticuerpos para radionúclidos quelados
EP4523704A1 (en) Camptothecin derivative and ligand-drug conjugate
JP2023510905A5 (enExample)
JP2022511351A5 (enExample)
JP2019069983A (ja) 新規抗体コンジュゲートおよびその使用
JP2020501531A5 (enExample)
JP2023505708A5 (enExample)
JP2013529059A5 (enExample)
RU2014113304A (ru) Анти-cd40-антитела, применение и методы
RU2017112884A (ru) Иммуноконъюгаты, содержащие антитела против her2 и пирролбензодиазепины
WO2019050780A1 (en) COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS
JP2023519261A5 (enExample)
TWI763956B (zh) 治療癌症的抗前胃泌激素抗體與免疫療法之組合療法
JP2024523422A (ja) 抗腫瘍化合物およびその応用
JP2023037000A (ja) 抗cd40抗体及びその使用
JP2025539841A5 (enExample)
JP2023536086A5 (enExample)
CN115998900A (zh) 抗trop-2抗体药物偶联物及其医药用途
KR20250048287A (ko) 새로운 티올 환원제, 제조 방법 및 용도
AU2022350725A1 (en) Antibody-drug conjugate, preparation method therefor, and pharmaceutical use thereof
RU2021135114A (ru) Конъюгат антитела к b7-h4 и лекарственного средства и его медицинское применение
RU2024107004A (ru) Анти-hla-g антитела
HK40119434A (en) Camptothecin derivative and ligand-drug conjugate
AU2023404588A1 (en) Anti-cldn18.2 antibody-drug conjugate, and pharmaceutical composition thereof and use thereof